UCHL1 and neuroendocrine carcinoma: Similarly, UCHL1 has increased expression in tissues and plasma from patients with neuroendocrine carcinomas [88], while tumor-derived C3a expression was elevated in serum samples of patients across multiple cancer types [89–91].